@article{CDT11311,
author = {Sameer Arora and Cassandra J. Ramm and Jacob A. Misenheimer and John P. Vavalle},
title = {Early transcatheter valve prosthesis degeneration and future ramifications},
journal = {Cardiovascular Diagnosis and Therapy},
volume = {7},
number = {1},
year = {2016},
keywords = {},
abstract = {Transcatheter aortic valve replacement (TAVR) has become the treatment of choice for patients with severe, symptomatic aortic stenosis with prohibitive risk for valve replacement surgery (SAVR) and is now considered a favourable alternative to surgical management for patients considered to be high risk (1). Recently published results of the PARTNER 2 trial have demonstrated that TAVR is an acceptable treatment option for patients with intermediate surgical risk and may hold an advantage over surgery if feasible via transfemoral approach (2). As we continue to explore the possibility of TAVR for lower risk patients who are typically younger and good candidates for surgical therapy, the durability of the prosthesis becomes an important consideration. Bioprosthetic valve failure after surgical aortic valve replacement (SAVR) is well described and well investigated. Structural valve deterioration is the most common noted cause with incidence of },
issn = {2223-3660}, url = {https://cdt.amegroups.org/article/view/11311}
}